Search Results 231-240 of 17272 for egfr

1. SER-262 Versus Placebo In Adults With Primary Clostridium Difficile Infection To Prevent Recurrence - Mayo Clinic

   Estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2; Admitted to or expected to be admitted to an intensive care unit for medical reasons (not ...

2. Phase 3 Study Of MRTX849 With Cetuximab Vs Chemotherapy In Patients With Advanced Colorectal Cancer With KRAS G12C Mutation - Mayo Clinic

   Prior treatment with an anti-EGFR antibody (e.g., cetuximab or panitumumab). Active brain metastasis. Participating Mayo Clinic locations. Study statuses ...

3. Primary Sclerosing Cholangitis Clinical Trials - Mayo Clinic Research

   Erlotinib (Tarceva) is a human EGFR type 1 tyrosine kinase inhibitor and offers greater survival benefit to EGFR positive patients. This study will assist ...

4. A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma or non-Hodgkin Lymphoma - Mayo Clinic

   - eGFR ≥ 30 mL/min/1.73 m^2, using the MDRD equation;; ANC ≥ 1000 mm^3 (≥ 1.0*10^ 9 /L); a count of ≥ 750/mm^3 (≥ 0.75*10^ 9/L) may be acceptable for ...

5. My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors - Mayo Clinic

   EGFR amplifications in the absence of EGFR-activating mutations; Cancers with exon 20 mutations; Previous treatment with erlotinib or any other EGFR inhibitor ...

6. Non Clinical Trials - Mayo Clinic Research

   ... EGFR mutated and cMET amplified advanced/metastatic non-small cell lung cancer,and have acquired resistance to prior EGFR tyrosine kinase inhibitors.

7. A Study Of Intravesical BCG In Combination With ALT-803 In Patients With Non-Muscle Invasive Bladder Cancer - Mayo Clinic

   using the following Cockcroft-Gault equation to calculate the eGFR for this study: eGFR in mL/min = {(140-age in years) x (weight in kg) x F}/(serum creatinine ...

8. Caloric Restriction in Autosomal Dominant Polycystic Kidney Disease - Mayo Clinic

   Males and Females ages 18-45 · Diagnosis of ADPKD with rapid progression as defined by class 1C to 1D by the imaging classification of Irazabal et al · eGFR (CD- ...

9. EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study) - Mayo Clinic

   Estimated glomerular filtration rate (eGFR) < 20 mL/min/1.73 m2 at baseline. Co-morbid conditions that may interfere with completing the study protocol ...

10. A Study To Evaluate Telisotuzumab Vedotin (ABBV-399) In Subjects With Previously Treated C-Met+ Non-Small Cell Lung Cancer - Mayo Clinic

    Histologically confirmed non-squamous cell non-small cell lung cancer (NSCLC) with known epidermal growth factor receptor (EGFR) status (wild type or mutant ...